Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status
ABSTRACT: Introduction: Up to 75% of women with ovarian cancer experience psychosexual morbidity and approximately 15–20% of women with ovarian cancer have a germline BRCA1/2 mutation (gBRCAm). However, psychosexual morbidity remains unexplored in women with gBRCAm ovarian cancer. Aim: Given their...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Oxford University Press
2022-02-01
|
| Series: | Sexual Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2050116121001458 |
| _version_ | 1797721080912150528 |
|---|---|
| author | Chloe A. Logue, MBChB, MRes Julia Pugh, BNurs (hons), MSc, PGDip Philip Foden, BSc, MSc Reem D. Mahmood, MBChB, MRCP Robert D. Morgan, MBBS Claire Mitchell, MBBS, MRCP, PhD Jurjees Hasan, MSc, MD, FRCP Andrew R. Clamp, MA, BMBCh, PhD Gordon C. Jayson, PhD, FRCP |
| author_facet | Chloe A. Logue, MBChB, MRes Julia Pugh, BNurs (hons), MSc, PGDip Philip Foden, BSc, MSc Reem D. Mahmood, MBChB, MRCP Robert D. Morgan, MBBS Claire Mitchell, MBBS, MRCP, PhD Jurjees Hasan, MSc, MD, FRCP Andrew R. Clamp, MA, BMBCh, PhD Gordon C. Jayson, PhD, FRCP |
| author_sort | Chloe A. Logue, MBChB, MRes |
| collection | DOAJ |
| description | ABSTRACT: Introduction: Up to 75% of women with ovarian cancer experience psychosexual morbidity and approximately 15–20% of women with ovarian cancer have a germline BRCA1/2 mutation (gBRCAm). However, psychosexual morbidity remains unexplored in women with gBRCAm ovarian cancer. Aim: Given their younger age, genetic diagnosis, breast cancer risk, and increased prevalence of surgically-induced menopause, we aim to assess whether women with gBRCAm ovarian cancer experience distinct psychosexual morbidity. Methods: Psychosexual morbidity was investigated in 2 cohorts of women with ovarian cancer: women with gBRCAm ovarian cancer vs women with gBRCA wildtype (gBRCAwt) ovarian cancer. Between August 2019 and March 2020, women with high-grade serous carcinoma of the ovary, Fallopian tube or primary peritoneum were approached in clinic or telephoned and invited to take part. Exclusion criteria included: women with alternative histology; women admitted from clinic; and women who lacked capacity to independently complete the questionnaire. The Female Sexual Function Index (FSFI) and background information were collected at a single time-point per patient. Scores below 26.55 were interpreted to suggest psychosexual dysfunction. Main Outcome Measure: Responses including total and domain FSFI scores, self-reported psychosexual problems and interest in psychosexual support were compared. Results: Of 103 women approached, 53% returned questionnaires. In this exploratory analysis, women with gBRCAm ovarian cancer were significantly younger (51–60 years vs 61–70 years, gBRCAwt, P = .010). There was a trend towards increased prevalence of surgical menopause (57% vs 27%, P = .097) and breast surgery (53% vs 22%, P = .132, gBRCAm vs gBRCAwt, respectively). Women with gBRCAm ovarian cancer scored higher in the FSFI questionnaire, particularly women under 60 years (15.1 vs 2.7, P = .070), approaching significance. Women with gBRCAm ovarian cancer expressed more interest for face-to-face services (P = .018), especially psychosexual therapy (65% vs 30%) and more often felt the service was insufficient, approaching significance (71% vs 44%, gBRCAm vs gBRCAwt, respectively, P = .076). Conclusion: Women with gBRCAm ovarian cancer are younger, express more interest for specialist psychosexual support and potentially different psychosexual problems, warranting further exploration.Logue C, Pugh J, Foden P, et al., Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status. Sex Med 2022;10:100465. |
| first_indexed | 2024-03-12T09:28:35Z |
| format | Article |
| id | doaj.art-b0123162747b48f18ee2caf28eb9129c |
| institution | Directory Open Access Journal |
| issn | 2050-1161 |
| language | English |
| last_indexed | 2024-03-12T09:28:35Z |
| publishDate | 2022-02-01 |
| publisher | Oxford University Press |
| record_format | Article |
| series | Sexual Medicine |
| spelling | doaj.art-b0123162747b48f18ee2caf28eb9129c2023-09-02T14:02:06ZengOxford University PressSexual Medicine2050-11612022-02-01101100465Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational StatusChloe A. Logue, MBChB, MRes0Julia Pugh, BNurs (hons), MSc, PGDip1Philip Foden, BSc, MSc2Reem D. Mahmood, MBChB, MRCP3Robert D. Morgan, MBBS4Claire Mitchell, MBBS, MRCP, PhD5Jurjees Hasan, MSc, MD, FRCP6Andrew R. Clamp, MA, BMBCh, PhD7Gordon C. Jayson, PhD, FRCP8The Christie NHS Foundation Trust, Manchester, UK; Corresponding Author: Dr Chloe Logue, MBChB, MRes, Gastro Respiratory Research, Level B1 Menzies Building, Waikato Hospital, Pembroke Street, 183, Private Bag 3200, Hamilton 3240, New Zealand. Tel: +64 (0) 07 839 8899The Christie NHS Foundation Trust, Manchester, UKThe Christie NHS Foundation Trust, Manchester, UKThe Christie NHS Foundation Trust, Manchester, UK; Manchester Cancer Research Centre, Division of Cancer Sciences, Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester, UKThe Christie NHS Foundation Trust, Manchester, UK; Manchester Cancer Research Centre, Division of Cancer Sciences, Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester, UKThe Christie NHS Foundation Trust, Manchester, UK; Manchester Cancer Research Centre, Division of Cancer Sciences, Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester, UKThe Christie NHS Foundation Trust, Manchester, UK; Manchester Cancer Research Centre, Division of Cancer Sciences, Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester, UKThe Christie NHS Foundation Trust, Manchester, UK; Manchester Cancer Research Centre, Division of Cancer Sciences, Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester, UKThe Christie NHS Foundation Trust, Manchester, UK; Manchester Cancer Research Centre, Division of Cancer Sciences, Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester, UKABSTRACT: Introduction: Up to 75% of women with ovarian cancer experience psychosexual morbidity and approximately 15–20% of women with ovarian cancer have a germline BRCA1/2 mutation (gBRCAm). However, psychosexual morbidity remains unexplored in women with gBRCAm ovarian cancer. Aim: Given their younger age, genetic diagnosis, breast cancer risk, and increased prevalence of surgically-induced menopause, we aim to assess whether women with gBRCAm ovarian cancer experience distinct psychosexual morbidity. Methods: Psychosexual morbidity was investigated in 2 cohorts of women with ovarian cancer: women with gBRCAm ovarian cancer vs women with gBRCA wildtype (gBRCAwt) ovarian cancer. Between August 2019 and March 2020, women with high-grade serous carcinoma of the ovary, Fallopian tube or primary peritoneum were approached in clinic or telephoned and invited to take part. Exclusion criteria included: women with alternative histology; women admitted from clinic; and women who lacked capacity to independently complete the questionnaire. The Female Sexual Function Index (FSFI) and background information were collected at a single time-point per patient. Scores below 26.55 were interpreted to suggest psychosexual dysfunction. Main Outcome Measure: Responses including total and domain FSFI scores, self-reported psychosexual problems and interest in psychosexual support were compared. Results: Of 103 women approached, 53% returned questionnaires. In this exploratory analysis, women with gBRCAm ovarian cancer were significantly younger (51–60 years vs 61–70 years, gBRCAwt, P = .010). There was a trend towards increased prevalence of surgical menopause (57% vs 27%, P = .097) and breast surgery (53% vs 22%, P = .132, gBRCAm vs gBRCAwt, respectively). Women with gBRCAm ovarian cancer scored higher in the FSFI questionnaire, particularly women under 60 years (15.1 vs 2.7, P = .070), approaching significance. Women with gBRCAm ovarian cancer expressed more interest for face-to-face services (P = .018), especially psychosexual therapy (65% vs 30%) and more often felt the service was insufficient, approaching significance (71% vs 44%, gBRCAm vs gBRCAwt, respectively, P = .076). Conclusion: Women with gBRCAm ovarian cancer are younger, express more interest for specialist psychosexual support and potentially different psychosexual problems, warranting further exploration.Logue C, Pugh J, Foden P, et al., Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status. Sex Med 2022;10:100465.http://www.sciencedirect.com/science/article/pii/S2050116121001458Ovar*BRCAPsychosex*Menopaus* |
| spellingShingle | Chloe A. Logue, MBChB, MRes Julia Pugh, BNurs (hons), MSc, PGDip Philip Foden, BSc, MSc Reem D. Mahmood, MBChB, MRCP Robert D. Morgan, MBBS Claire Mitchell, MBBS, MRCP, PhD Jurjees Hasan, MSc, MD, FRCP Andrew R. Clamp, MA, BMBCh, PhD Gordon C. Jayson, PhD, FRCP Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status Sexual Medicine Ovar* BRCA Psychosex* Menopaus* |
| title | Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status |
| title_full | Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status |
| title_fullStr | Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status |
| title_full_unstemmed | Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status |
| title_short | Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status |
| title_sort | psychosexual morbidity in women with ovarian cancer evaluation by germline brca gene mutational status |
| topic | Ovar* BRCA Psychosex* Menopaus* |
| url | http://www.sciencedirect.com/science/article/pii/S2050116121001458 |
| work_keys_str_mv | AT chloealoguembchbmres psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus AT juliapughbnurshonsmscpgdip psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus AT philipfodenbscmsc psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus AT reemdmahmoodmbchbmrcp psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus AT robertdmorganmbbs psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus AT clairemitchellmbbsmrcpphd psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus AT jurjeeshasanmscmdfrcp psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus AT andrewrclampmabmbchphd psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus AT gordoncjaysonphdfrcp psychosexualmorbidityinwomenwithovariancancerevaluationbygermlinebrcagenemutationalstatus |